Abstract

TPS2081 Background: Cytotoxic drug delivery to high grade glioma (HGG) is limited by the blood brain barrier (BBB). Convection-enhanced delivery (CED) improves chemotherapy delivery by utilizing fl...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
AT-25 * A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
S Han ... N Butowski
Neuro-oncology | VOL. 16
S Han, et. al.S Han ... N Butowski
01 Nov 2014
A PHASE I STUDY OF CONVECTION-ENHANCED DELIVERY OF LIPOSOMAL-IRINOTECAN USING REAL-TIME IMAGING WITH GADOLINIUM IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA
N Butowski ... K Bankiewicz
Neuro-oncology | VOL. 16
N Butowski, et. al.N Butowski ... K Bankiewicz
01 Jul 2014
Convection-Enhanced Delivery of Nimustine Hydrochloride for Recurrent Spinal Cord High-grade Glioma
Toshiki Endo ... Teiji Tominaga
Neurosurgery | VOL. 66
Toshiki Endo, et. al.Toshiki Endo ... Teiji Tominaga
20 Aug 2019
Regression of Recurrent Spinal Cord High-Grade Glioma After Convection-Enhanced Delivery of Nimustine Hydrochloride: Case Reports and Literature Review.
Toshiki Endo ... Tomoo Inoue
Operative neurosurgery (Hagerstown, Md.) | VOL. 18
Toshiki Endo, et. al.Toshiki Endo ... Tomoo Inoue
01 Apr 2020
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.
Yoon-Koo Kang ... Sung Hoon Noh
Journal of Clinical Oncology | VOL. -
Yoon-Koo Kang, et. al.Yoon-Koo Kang ... Sung Hoon Noh
12 Jul 2024
Individualized Local Recurrence Estimates for Ductal Carcinoma In Situ.
Laura E G Warren ... Jennifer R Bellon
Journal of Clinical Oncology | VOL. -
Laura E G Warren, et. al.Laura E G Warren ... Jennifer R Bellon
11 Jul 2024
Are Oral Selective Estrogen Receptor Degraders Beneficial for Patients With ESR1-Mutated Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer?
Aoba Okeya ... Chikako Shimizu
Journal of Clinical Oncology | VOL. -
Aoba Okeya, et. al.Aoba Okeya ... Chikako Shimizu
11 Jul 2024
Reply to A. Okeya et al.
Miguel Martín ... Joohyuk Sohn
Journal of Clinical Oncology | VOL. -
Miguel Martín, et. al.Miguel Martín ... Joohyuk Sohn
11 Jul 2024
View more papers